Phencyclidine (PCP) & Injectable opiates
Phencyclidine (PCP), also known as angel dust, is a dissociative drug that acts primarily as an NMDA receptor antagonist. NMDA receptors are a type of receptor for the neurotransmitter glutamate, which is involved in various brain functions. By blocking NMDA receptors, PCP disrupts the normal functioning of glutamate, leading to altered communication between brain cells.
NMDA receptors play a crucial role in synaptic plasticity, learning, memory, and perception. PCP's blockade of NMDA receptors reduces the flow of calcium ions into neurons, interfering with their normal activation. This disruption results in a decrease in the release of other neurotransmitters, such as dopamine and serotonin, which can lead to changes in mood, perception, and cognition.
At lower doses, PCP may induce feelings of euphoria, relaxation, and detachment from one's surroundings. Users may experience a sense of dissociation from their body, leading to the term "dissociative anesthetic." Higher doses can lead to hallucinations, delirium, agitation, and potentially dangerous behaviors. Users may become disoriented, experience distorted perceptions, and exhibit unpredictable or violent behavior.
Injectable opiates, such as morphine or heroin, belong to the class of opioids. These substances primarily bind to opioid receptors, which are located in various regions of the brain, spinal cord, and peripheral nervous system.
There are several types of opioid receptors, with the mu-opioid receptor being the primary target. When an opiate binds to a mu-opioid receptor, it activates a cascade of events within the neuron. Activation of the mu-opioid receptor inhibits the release of neurotransmitters involved in pain signaling, such as substance P, glutamate, and noradrenaline. This inhibition of neurotransmitter release reduces the transmission of pain signals from the periphery to the brain.
Opiates can induce feelings of euphoria, sedation, and relaxation, primarily mediated by the activation of reward pathways in the brain. Opioids can also affect other physiological processes, such as respiratory rate, gastrointestinal motility, and emotional regulation.
PCP and injectable opiates have contrasting effects on the CNS, which can lead to unpredictable and dangerous outcomes. When PCP and injectable opiates are combined, their effects can interact synergistically, intensifying the risks and complications.
The combination can lead to severe CNS depression, including respiratory depression, which can be life-threatening. The individual may experience extreme confusion, impaired judgment, and loss of motor control, increasing the likelihood of accidents or injuries.
The risk of overdose is significantly higher when these substances are combined, as their effects on the respiratory system can suppress breathing to dangerous levels.
It is worth considering, although indirect and secondary, but the cross-influence of both substances on the glutamate system. This, and the ability of PSP mentioned in some sources to reduce the body's tolerance to opioids, significantly increases the risks of overdose and life-threatening conditions.
All things considered, we recommend avoiding this combination under any conditions.
Last edited by a moderator: